Apixaban removal during emergency surgery for type A acute aortic dissection: a prospective cohort study.

ABSTRACT:

Background

Acute type A aortic dissection (ATAAD) has a high mortality, and acute aortic repair is the only curative treatment. In patients treated with factor Xa (FXa) inhibitors, the risk of severe disease-related complications such as cardiac tamponade and hemodynamic shock must be balanced against the potential for severe perioperative bleeding. The aim was to study intraoperative changes in plasma levels of the FXa inhibitor apixaban when using hemoadsorption during acute thoracic aortic repair.

Materials and methods

This is a single-center prospective cohort study. Eight apixaban-treated patients presenting with ATAAD underwent acute thoracic aortic repair with intraoperative hemoadsorption with CytoSorb. Apixaban concentrations were measured at the start of cardiopulm

SUBMITTER: Roed-Undlien H 

PROVIDER: S-EPMC11634093 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature